secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0000950170-25-106924
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q2 net loss $14.6M; setrusumab Phase 3 data due year-end 2025
-----------------------------------------------------------------------------

- Net loss of $14.6M in Q2 2025 vs $12.3M in Q2 2024; cash $56.1M as of June 30, 2025.
- Phase 3 Orbit and Cosmic studies of setrusumab in OI on track for final analysis around year-end 2025.
- DMC interim analysis in July 2025 confirmed acceptable safety for setrusumab; study continues to final analysis.
- R&D expenses $5.4M (+$0.4M YoY) driven by setrusumab manufacturing; G&A down $2.4M to $5.5M.
- Alvelestat partnering discussions ongoing; cash expected to fund operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/0000950170-25-106924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/mreo-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer